Finder makes money from featured partners, but editorial opinions are our own.

How to buy Enlitic (ENL) shares in Australia

Learn how to easily invest in Enlitic shares.

Enlitic is a health information services business based in Australia. Enlitic shares (ENL) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Enlitic has a trailing 12-month revenue of around $495,918. If you're looking to buy shares, check out the steps below.

How to buy shares in Enlitic

To buy shares listed in Australia such as Enlitic, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.

  1. Open and fund your brokerage account.
    Complete an application with your personal and financial details, including your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  2. Search for Enlitic.
    Find the share by name or ticker symbol: ENL. Research its history to confirm it's a solid investment against your financial goals.
  3. Purchase now or later.
    Buy today with a market order or use a limit order to delay your purchase until Enlitic reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
  4. Decide on how many to buy.
    At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  5. Check on your investment.
    Congratulations, you own a part of Enlitic. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.

Enlitic stock price (ASX:ENL)

Use our graph to track the performance of ENL stocks over time.

Enlitic shares at a glance

Information last updated 2024-07-11.
52-week range$0.12 - $1.01
50-day moving average $0.2799
200-day moving average $0.5629
Target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.82

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Name Product Standard brokerage fee Inactivity fee Asset class
Finder AwardExclusive
US$10 per month if there’s been no log-in for 12 months
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
CFD service. Capital at risk.
Join the world's biggest social trading network when you trade stocks, commodities and currencies from the one account.
Moomoo Share Trading
ASX shares, Global shares, US shares, ETFs
Get 10 free shares + earn 6.8% p.a. on idle cash upon deposit. T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 20 million investors.
Tiger Brokers
Tiger Brokers
ASX shares, Global shares, US shares, ETFs
Finder exclusive: 10 no-brokerage US or ASX market trades in the first 180 days + 7% p.a. on uninvested cash with first deposit of any amount, plus US$30 TSLA + US$30 NVDA shares with deposits up to AU$2000. T&Cs apply.
Trade Australian, US and Asian stocks with no minimum deposit on Tiger Broker’s feature-packed platform.
CMC Invest
Finder Award
CMC Invest
ASX shares, Global shares, Options trading, US shares, ETFs
$0 brokerage on US, UK, Canadian and Japanese markets (FX spreads apply).
Trade over 45,000 shares and ETFs from Australia and 15 major global markets. Plus, buy Aussie shares or ETFs for $0 brokerage up to $1,000 (First buy order of each security, each day - excludes margin loan settled trades).
ASX shares, Global shares, Options trading, US shares, ETFs
Finder exclusive: Get an additional 30 days of $0 brokerage. Get advanced research and trading tools with $0 brokerage and free lvl 2 NASDAQ stock data for 30 days. T&Cs apply.
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.

Is it a good time to buy Enlitic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Enlitic financials

Revenue TTM $495,918
Gross profit TTM $0
Return on assets TTM -121.7%
Return on equity TTM 0%
Profit margin 0%
Book value 0.127
Market capitalisation $12.3 million

TTM: trailing 12 months

Enlitic share dividends

We're not expecting Enlitic to pay a dividend over the next 12 months.

Enlitic overview

Enlitic, Inc. operates in the healthcare IT sector in the United States, Europe, and Japan. The company uses artificial intelligence (AI) to develop software products that manage medical imaging data in radiology, such as magnetic resonance imaging, computed tomography scans, X-ray, and ultrasound images, and licenses such products to healthcare providers and original equipment manufacturers. Its healthcare data solutions include ENDEX, a medical imaging solution that standardizes and structures data from medical images; and ENCOG, a solution designed to de-identify medical imaging data while retaining clinically relevant information. The company also offers Enlitic Curie, an extensible data management framework powered by AI that allows easy implementation and orchestration of Enlitic application modules. It provides solutions to radiologists, IT and PACS administrators, hospital executives, and researchers. The company was formerly known as You Partners, Inc. Enlitic, Inc. was incorporated in 2014 and is based in Fort Collins, Colorado.

Enlitic in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask a Question

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms Of Service and Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site